Bear Stearns Downgrades Momenta Pharmaceuticals (MNTA) to Peer Perform
More News related to MNTA
- After-Hours Movers 6/29: HRB, MNTA, APOL Higher
- Momenta Pharmaceuticals (MNTA) Announces Results From the M118 EMINENCE Trial
- Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
- Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors
- Momenta Pharmaceuticals to Present At the Goldman Sachs 30th Annual Global Healthcare Conference
Bear Stearns downgrades Momenta Pharmaceuticals (Nasdaq: MNTA) from Outperform to Peer Perform.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. [BCS]
Related Categories
DowngradesStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
